On 2026-09-16, Stifel initiated coverage of ROIV with a Buy rating.
Stifel 于 2026-09-16 首次覆盖 ROIV，初始评级为 买入（Buy）。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
TD Cowen raises ROIV target to $55TD Cowen 上调目标价 ROIV 至 $55
Rating Change · September 9, 2026评级变动 · 2026/9/9
Guggenheim raises ROIV target to $46Guggenheim 上调目标价 ROIV 至 $46
Rating Change · September 9, 2026评级变动 · 2026/9/9
ROIV regulatory decision: US FDA approves Roivant-Priovant's skin and muscle disease drugRoivant Sciences Ltd.（ROIV）的 产品 获美国 FDA 许可或批准
Material Company Event · August 27, 2026公司公告 · 2026/8/27
